drugset / Trial / NCT07461454
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The study will evaluate the safety and efficacy of YL202, when compared with treatment of physician's choice (eribulin, capecitabine, vinorelbine, gemcitabine or sacituzumab govitecan) in participants with unresectable locally advanced, recurrent or metastatic hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer who had failed at least one line of chemotherapy.
Timeline
- Start
- 2026-03-17
- Primary completion
- 2027-12-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Comparator | Capecitabine | Small molecule | 1250 mg/m2 | — |
| Comparator | Eribulin | Small molecule | 1.4 mg/m2 | Intravenous |
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Comparator | Sacituzumab Govitecan | Monoclonal antibody | 10 mg/kg | Intravenous |
| Comparator | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |
| Subject | YL202 | Unknown | — | Intravenous |